Cormedix Inc. · NASDAQ:CRMD
Cormedix — Investor Presentation (June 2022)
15 slides from Cormedix's investor presentation, Jun 15, 2022
Slide 1: Corporate Presentation
Corporate Presentation June 15, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Th
Slide 3: CorMedix is an Attractive Investment Opportunity, with Our Lead Product DefenCath
CorMedix is an Attractive Investment Opportunity, with Our Lead Product DefenCathTM Targeting Substantial Market Opportunities DefenCath is intended initially for CVCs used by hemodialysis patients with kidney failure to reduce the risk of catheter related blood stream infections (CRBSI) Addressing
Slide 4: CorMedix Executive Leadership Team
CorMedix Executive Leadership Team Joe Todisco Matt David, MD Phoebe Mounts, PhD, JD Liz Masson Hurlburt EVP, General Counsel, Legal, Chief Executive Officer EVP, Chief Financial Officer EVP, Clinical and Medical Affairs Regulatory, Compliance/Tech Ops Joined CorMedix in 2022 Joined CorMedix in 2020
Slide 5: Developing DefenCath: Multiple Potential Therapeutics Areas
Developing DefenCath: Multiple Potential Therapeutics Areas • No pharmacologic agents approved in the U.S. for the prevention or reduction of CRBSI in central venous catheters • DefenCath is an antimicrobial catheter lock solution designed to reduce CRBSIs and clotting • Broad antimicrobial activity
Slide 6: Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use
Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use Disease Burden Health Economics ~80% of patients starting HD will have a CVC inserted for HD patients with CRBSIs have almost 2x more vascular access 1 hospitalizations per year 4 CRBSIs can occ
Slide 7: Safety Net and Certain Racial Groups Have a Higher Rate of CVC use
Safety Net and Certain Racial Groups Have a Higher Rate of CVC use, Resulting in a Disproportionate Healthcare Burden Healthcare inequities are a primary focus of CMS The uninsured have nearly a 4x increase in the odds of having a CVC at dialysis initiation compared to Medicaid patients 13 Limited s
Slide 8: Phase 3 LOCK-IT-100 – Compelling Clinical Profile
Phase 3 LOCK-IT-100 – Compelling Clinical Profile 3 Objective to demonstrate the efficacy and safety of Interim Analysis Full Study DefenCath as a catheter lock solution for the prevention of Total CRBSIs (D / H) 28 (6 D / 22 H) 41 (9 D / 32 H) CRBSI and the incidence of treatment-emergent adverse e
Slide 9: Large Addressable Market Opportunity in Hemodialysis
Large Addressable Market Opportunity in Hemodialysis (Inpatient + Outpatient) Setting Of Care Addressable Market Reimbursement Dynamics NTAP (New Technology Add-On Payment) is an additional payment for drugs that 2.5mm-4mm* lumen locks per exceed a DRG payment amount by at least one standard deviati
Slide 10: NTAP, TDAPA & Separate Reimbursement
NTAP, TDAPA & Separate Reimbursement HOSPITAL INPATIENT SEPARATELY NTAP 9 New Technology Add-on Payment REIMBURSABLE Unique J Code (HCPCS Code) DefenCath application for NTAP has been reviewed favorably by CMS What is it? Additional payment for drugs that exceed a DRG payment amount by at least one
Slide 11: Commercial Execution Focus
Commercial Execution Focus Hospital (Inpatient) Dialysis Facility (Outpatient) A commercial organization of ~30 can provide A highly focused internal team of ~12 can provide adequate coverage for launch adequate coverage for launch: ~6,100 hospitals in the US, per AHA statistics There are ~7,600 dia
Slide 12: DefenCath Regulatory Status & Timeline
DefenCath Regulatory Status & Timeline • DefenCath granted Fast Track designation by FDA recognizing potential to address unmet medical need, as well as QIDP (Qualified Infectious Disease Product), which provides an additional 5 years of market exclusivity • DefenCath NDA granted rolling submission
Slide 13: Financial Highlights
Financial Highlights Key Statistics Balance Sheet Exchange NASDAQ Global Market Cash and short-term investments* $61.7 million** Common Stock 39.1 million shares as of 5/10/2022 Debt None Market cap ~$125 million * Excluding restricted cash ** as of 3/31/2022 CONFIDENTIAL AND NOT FOR DISTRIBUTION WI
Slide 14: CorMedix Key Investment Highlights
CorMedix Key Investment Highlights DefenCath is a novel product • ~80% of patients starting HD will have a CVC inserted for vascular access addressing a significant unmet • $2.3 billion spent annually on CRBSI medical need Compelling Efficacy and • 71% reduction in risk of CRBSI Safety Profile • Hig
Slide 15: References
References 1. USRDS End Stage Renal Disease 2020 Annual Data Report; Chapter 3; Vascular Access 2. Araya S. et.al.; Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population JASN 31: 625–636, 2020 3. LOCK-IT-100: CRMD003, A Novel Tauroline-Based Catheter